BiotechTube

Etanercept + Triamcinolone Acetonide

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Gout Attack

Conditions

Gout Attack

Trial Timeline

Oct 25, 2019 → Aug 13, 2021

NCT ID
NCT03636373

About Etanercept + Triamcinolone Acetonide

Etanercept + Triamcinolone Acetonide is a approved stage product being developed by Amgen for Gout Attack. The current trial status is terminated. This product is registered under clinical trial identifier NCT03636373. Target conditions include Gout Attack.

What happened to similar drugs?

11 of 20 similar drugs in Gout Attack were approved

Approved (11) Terminated (2) Active (8)
✅LumiracoxibNovartisApproved
✅Pegloticase + MethotrexateAmgenApproved
✅Pegloticase + Methotrexate (MTX)AmgenApproved
✅Pegloticase + Methotrexate (MTX) + Standard Gout Flare Prophylaxis + Infusion Reaction (IR) ProphylaxisAmgenApproved
✅Pegloticase + methotrexate + placebo + gout flare prophylaxis regimen + fexofenadine + acetaminophen + methylprednisoloneAmgenApproved
✅PegloticaseAmgenApproved
✅Pegloticase + Methotrexate (MTX)AmgenApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03636373ApprovedTerminated

Competing Products

20 competing products in Gout Attack

See all competitors
ProductCompanyStageHype Score
febuxostat + AllopurinolAstellas PharmaPhase 3
40
Dotinurad + FebuxostatEisaiPhase 3
40
BaricitinibEli LillyPhase 2
35
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 1
25
SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tabletJiangsu Hengrui MedicinePhase 2
31
repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placeboJiangsu Hengrui MedicinePhase 1
29
SHR4640 + placeboJiangsu Hengrui MedicinePhase 1
29
SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
40
Colchicine + Febuxostat + SHR4640Jiangsu Hengrui MedicinePhase 1
29
SHR4640 + AllopurinolJiangsu Hengrui MedicinePhase 3
40
SHR4640 ；Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + FebuxostatJiangsu Hengrui MedicinePhase 2
42
SHR4640Jiangsu Hengrui MedicinePhase 1
25
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
47
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
40
SHR4640 + PlaceboJiangsu Hengrui MedicinePhase 1
29
Zurampic® + Control group: xanthine oxidase inhibitor monotherapyAstraZenecaPre-clinical
18
Risk of selected safety eventsAstraZenecaPre-clinical
26
AZD6140 + Placebo to match AZD6140AstraZenecaPhase 1
29
RDEA3170 + Allopurinol + PlaceboAstraZenecaPhase 2
35
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
32